Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Sopheon Funding Award

19 Oct 2017 07:00

RNS Number : 9906T
Sopheon PLC
19 October 2017
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon Awarded Funding for European Research Projects

 

Funding recognizes Sopheon's ongoing contribution to research on market disrupters such as Internet of Things, real-time decision support, and advanced analytics embedded into business process

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today announced the award of European funding for innovative research in the framework of the EUREKA/ITEA research program alongside a consortium of project partners. The funding is for two different projects, Medolution (https://itea3.org/project/medolution.html) and PARTNER (https://itea3.org/project/partner.html).

 

Both research projects focus on developing innovative and intelligent methods and software for real time handling of massive volumes of data across complex scenarios, with emphasis on the healthcare industry. Sopheon's contribution to these projects focuses on applying the data-driven decision support capabilities of our Accolade® software. Sopheon benefits in return from the collaboration with project partners − research institutes and leading software companies such as Philips Healthcare, Atos/Bull, Siemens Healthcare, Barco, IMEC, KPN and NXP Semiconductors - to develop breakthrough capabilities for commercial application in our software.

 

In the current digital age, organizations are looking for technologies that allow them to handle unprecedented amounts of information, with speed. This information is drawn from a very incoherent landscape of IT systems and sources, within as well as beyond the physical boundaries of the enterprise. The data to be handled comes from many different sources - structured and unstructured data; metadata from sensor data, images, video - and is reused in the context of big data analysis, internet of things (IoT) techniques, cloud services, etc.

 

The Accolade software is able to interpret all of this data in real time, irrespective of source or format, based on rules and criteria defined by domain experts and within predefined best practice protocols that are managed by the Accolade system.

 

Huub Rutten, VP Research and Application Development at Sopheon, stated: "For Sopheon the research is very applicable to our core enterprise innovation management clients and future product strategy. Our work in these projects positions us to develop relationships with some of the leading companies in the world for commercial leverage, and to develop innovative strategic technologies and applications for our target markets. Further, our research discoveries also have the potential to open new market segments for our application."

 

This award brings to a total of five the number of research grants awarded to Sopheon since 2009.

 

Sopheon® and Accolade® are trademarks of Sopheon 

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

 

About Eureka. EUREKA (http://www.eurekanetwork.org/) is an intergovernmental organization for pan-European research and development funding and coordination. EUREKA aims to coordinate efforts of governments, research institutes and commercial companies concerning innovation.

 

About ITEA. ITEA (https://itea3.org/) is the EUREKA Cluster program supporting innovative, industry-driven, pre-competitive R&D projects in the area of Software-intensive Systems & Services (SiSS). ITEA stimulates projects in an open community of large industry, SMEs, universities, research institutes, and user organizations.

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKFDNQBDDQKD
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSHolding(s) in Company
1st Oct 20127:00 amRNSDirectors' Options
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.